A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

This study is testing a new experimental medication called AZD9592 to see how well it works against advanced solid tumors, either on its own or with other common cancer treatments. Because this is a first-in-human trial, the primary goal is to find the right dose and ensure the treatment is safe for patients.

This study is for adults 18 and older with advanced cancers, such as lung, colon, or head and neck cancer, who are still mobile and active. Participants must have organs that are functioning well and tumors that are clearly visible on scans to help doctors track the treatment's impact.

You will receive the experimental medication, possibly alongside other proven cancer therapies, while the medical team closely monitors your health and how your body reacts to the treatment. You will undergo regular check-ups, blood tests, and scans to help researchers learn how to best fight your cancer.

The study is currently active but not looking for new participants, and it is being held at specialized cancer centers in California, Connecticut, and Washington D.C. Please talk to your oncology team if you are interested in similar research opportunities.